Neurocrine Biosciences, Inc.
NBIX
$108.31
$1.311.22%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.84% | 24.72% | 30.37% | 22.57% | 25.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.84% | 24.72% | 30.37% | 22.57% | 25.05% |
| Cost of Revenue | 33.49% | 32.33% | 27.34% | 12.77% | 16.15% |
| Gross Profit | 17.23% | 21.34% | 31.99% | 27.90% | 28.96% |
| SG&A Expenses | 37.87% | 14.74% | 9.11% | 0.16% | 19.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.12% | 22.29% | 16.67% | 4.94% | 18.24% |
| Operating Income | -12.84% | 30.88% | 100.95% | 254.55% | 45.36% |
| Income Before Tax | -17.96% | 64.62% | -18.91% | 133.40% | 68.11% |
| Income Tax Expenses | 17.82% | 86.15% | 28.74% | 66.67% | 74.74% |
| Earnings from Continuing Operations | -30.20% | 56.20% | -31.94% | 156.66% | 65.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.20% | 56.20% | -31.94% | 156.66% | 65.96% |
| EBIT | -12.84% | 30.88% | 100.95% | 254.55% | 45.36% |
| EBITDA | -11.47% | 30.40% | 97.20% | 221.33% | 44.71% |
| EPS Basic | -31.31% | 51.26% | -34.10% | 155.13% | 62.41% |
| Normalized Basic EPS | -10.73% | 29.49% | 96.07% | 223.26% | 49.58% |
| EPS Diluted | -30.74% | 51.22% | -33.68% | 153.16% | 64.77% |
| Normalized Diluted EPS | -9.81% | 29.62% | 95.28% | 211.41% | 50.60% |
| Average Basic Shares Outstanding | 1.63% | 3.27% | 3.28% | 2.78% | 2.18% |
| Average Diluted Shares Outstanding | 0.59% | 3.17% | 3.69% | 6.69% | 1.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
